Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine

被引：45

作者：

Coelmont, Lotte

Paeshuyse, Jan

Windisch, Marc P.

De Clercq, Erik

Bartenschlager, Ralf

Neyts, Johan

机构：

[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

[2] Univ Heidelberg, Dept Mol Virol, D-69120 Heidelberg, Germany

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 10期

关键词：

D O I：

10.1128/AAC.00372-06

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Ribavirin antagonizes the in vitro anti-hepatitis C virus (HCV) activity of the pyrimidine nucleoside analogue 2'-C-methyleytidine, the active component of the experimental anti-HCV drug valopicitabine. In contrast, the combination of ribavirin with either the purine nucleoside analogue 2'-C-methyladenosine or the HCV protease inhibitor VX-950 resulted in an additive antiviral activity. These findings may have implications when planning clinical studies with valopicitabine.

引用

收藏

页码：3444 / 3446

页数：3

相关论文

共 13 条

[1]

Afdhal N, 2004, HEPATOLOGY, V40, p726A

[2] RIBAVIRIN ANTAGONIZES INHIBITORY EFFECTS OF PYRIMIDINE 2',3'-DIDEOXYNUCLEOSIDES BUT ENHANCES INHIBITORY EFFECTS OF PURINE 2',3'-DIDEOXYNUCLEOSIDES ON REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS INVITRO [J].

BABA, M ;

PAUWELS, R ;

BALZARINI, J ;

HERDEWIJN, P ;

DECLERCQ, E ;

DESMYTER, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (10) :1613-1617

[3] Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs [J].

Carroll, SS ;

Tomassini, JE ;

Bosserman, M ;

Getty, K ;

Stahlhut, MW ;

Eldrup, AB ;

Bhat, B ;

Hall, D ;

Simcoe, AL ;

LaFemina, R ;

Rutkowski, CA ;

Wolanski, B ;

Yang, ZC ;

Migliaccio, G ;

De Francesco, R ;

Kuo, LC ;

MacCoss, M ;

Olsen, DB .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (14) :11979-11984

[4] Challenges and successes in developing new therapies for hepatitis C [J].

De Francesco, R ;

Migliaccio, G .

NATURE, 2005, 436 (7053) :953-960

[5] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].

Fried, MW ;

Shiffman, ML ;

Reddy, KR ;

Smith, C ;

Marinos, G ;

Goncales, FL ;

Haussinger, D ;

Diago, M ;

Carosi, G ;

Dhumeaux, D ;

Craxi, A ;

Lin, A ;

Hoffman, J ;

Yu, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982

[6] In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance [J].

Le Pogam, Sophie ;

Jiang, Wen-Rong ;

Leveque, Vincent ;

Rajyaguru, Sonal ;

Ma, Han ;

Kang, Hyunsoon ;

Jiang, Sharon ;

Singer, Margaret ;

Ali, Samir ;

Klumpp, Klaus ;

Smith, Dave ;

Symons, Julian ;

Cammack, Nick ;

Najera, Isabel .

VIROLOGY, 2006, 351 (02) :349-359

[7] The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro [J].

Paeshuyse, J ;

Kaul, A ;

De Clercq, E ;

Rosenwirth, B ;

Dumont, JM ;

Scalfaro, P ;

Bartenschlager, R ;

Neyts, J .

HEPATOLOGY, 2006, 43 (04) :761-770

[8] A 3-DIMENSIONAL MODEL TO ANALYZE DRUG-DRUG INTERACTIONS [J].

PRICHARD, MN ;

SHIPMAN, C .

ANTIVIRAL RESEARCH, 1990, 14 (4-5) :181-206

[9] Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C [J].

Reiser, M ;

Hinrichsen, H ;

Benhamou, Y ;

Reesink, HW ;

Wedemeyer, H ;

Avendano, C ;

Riba, N ;

Yong, CL ;

Nehmiz, G ;

Steinmann, GG .

HEPATOLOGY, 2005, 41 (04) :832-835

[10]

Stuyver Lieven J., 2006, Antiviral Chemistry & Chemotherapy, V17, P79